<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303574</url>
  </required_header>
  <id_info>
    <org_study_id>D6190C00001</org_study_id>
    <secondary_id>2014-004043-13</secondary_id>
    <nct_id>NCT02303574</nct_id>
  </id_info>
  <brief_title>Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study</brief_title>
  <official_title>A PHASE I, RANDOMISED, SINGLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND FOOD EFFECT OF SINGLE AND MULTIPLE ORAL DOSES OF AZD7986 IN HEALTHY VOLUNTEERS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the
      safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and
      multiple oral doses of AZD7986 in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2014</start_date>
  <completion_date type="Actual">August 3, 2016</completion_date>
  <primary_completion_date type="Actual">August 3, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a and 1b) and Multiple Ascending Doses (MAD -Part 2)</measure>
    <time_frame>Part 1a and 1b: Day -1, Day 1 to Day 3 (spontaneous, at pre-dose, 3, 12, 24, 48 and 72 hours [h] post-dose), Day 4, Day 5 and follow-up (7-10 days after dosing [not for participants included in Part 1b]); Part 2: Day -1, Day 1 to Day 21/28 and follow-up</time_frame>
    <description>To investigate the safety and tolerability of AZD7986 by assessment of AEs (non-serious and serious) following administration of oral solution in SAD (Part 1a - fasted state and 1b - fed state) and MAD (Part 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Note: Day 1 data calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCτ) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. AUCτ: AUC from time zero to 24 hours post-dose presented on Day1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assessthe observed maximum plasma concentration (Cmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Cmax was taken directly from the individual concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the time to reach maximum observed concentration (tmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the apparent terminal elimination half-life (t½.λz) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve. Note: Day 1 data were calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the mean residence time (MRT) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the apparent clearance (CL/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; CL/F for parent drug was estimated as dose divided by AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the the apparent volume of distribution (Vz/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the accumulation ratio for (Rac(AUC(0-τ)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC(0-24) Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the accumulation ratio for Cmax (Rac(Cmax)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as Cmax Day 21/Cmax Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess the temporal change parameter (TCP) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC Day 1, if extrapolated part was less than 20%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess renal clearance from 0 to 48 hours (CLR0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess cumulative amount of analyte excreted from 0 to 24 hours (CumAe0-24) for Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess percentage of dose excreted unchanged into the urine from 0 to 24 hours (Cumfe0 24) for Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess renal clearance from 0 to 24 hours (CLR0-24) for Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess Cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48)) for Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MAD</measure>
    <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
    <description>To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the effect of food by evaluating the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the effect of food by evaluating the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the effect of food by evaluating the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the effect of food by evaluating the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the effect of food by evaluating the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the effect of food by evaluating the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the effect of food by evaluating the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD</measure>
    <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
    <description>To assess the effect of food by evaluating the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Mean Normalized Relative Neutrophil Elastase (NE) Activity in All Cohorts of Part 2</measure>
    <time_frame>At Day 16, 21 ((last dosing day in Cohort 1), 25, 28 (last sampling day in Cohort 1 and last dosing day in Cohorts 2 and 3), 32, 38, 41 and 52</time_frame>
    <description>Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Absolute Neutrophil Count (ANC) in All Cohorts of Part 2</measure>
    <time_frame>At Day 12 (pre-dose, 6 hours and 12 hours)</time_frame>
    <description>Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Safety, Pharmacokinetics, Pharmacodynamics, Food Effect</condition>
  <arm_group>
    <arm_group_label>AZD7986, single and mulltiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, single and multiple doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7986, oral solution, 1 to 50 mg/mL</intervention_name>
    <description>Starting dose in single ascending dose part: 5 mg</description>
    <arm_group_label>AZD7986, single and mulltiple doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, oral solution</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo, single and multiple doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated written informed consent prior to any study specific
             procedures.

          2. Healthy male or female subjects aged 18 to 50 years (inclusive) at screening with
             suitable veins for cannulation or repeated venepuncture.

          3. Females must be of non-child-bearing potential, confirmed at screening by fulfilling
             one of the following criteria:

               -  Post-menopausal defined as amenorrhoea for at least 12 months or more following
                  cessation of all exogenous hormonal treatments and follicle stimulating hormone
                  (FSH) and luteinising hormone (LH) levels in the post menopausal range.

               -  Documentation of irreversible surgical sterilisation by hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy but not tubal ligation.

          4. Male subjects must be non fertile, i.e., surgically sterilised with documentation of
             azoospermia or must practice an effective contraceptive method to prevent pregnancies.
             Effective contraceptive methods are:

               -  Sexual abstinence from before the first administration of the IMP until 3 months
                  after final administration of the IMP, only if this is in line with the preferred
                  and usual lifestyle of the subject.

               -  Use of a condom plus spermicide agent in addition to having their partner use
                  another acceptable method (oral or injectable hormonal contraceptives,
                  contraceptive patch, intrauterine devices, vaginal hormonal rings, vaginal
                  diaphragm or cervical caps) from before the first administration of the IMP until
                  3 months after final administration of the IMP.

               -  Subject's sexual partner is of non childbearing potential, i.e., post menopausal
                  or surgically sterilised (e.g., tubal ligation, hysterectomy in medical history).

          5. Have a body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive and weigh at least
             50 kg and no more than 100 kg inclusive at screening.

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study.

          -  History or presence of gastrointestinal, hepatic or renal disease, or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs.

          -  Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks
             of the first administration of IMP.

          -  Subject has increased risk of infection:

               -  History and/or presence of tuberculosis (TB); positive result for interferon
                  gamma release assay (IGRA) (i.e., QuantiFERON TB-Gold), subjects who have resided
                  in regions where tuberculosis and mycosis are endemic during 90 days before
                  screening, or who intend to visit such a region during the duration of the study
                  i.e. deserts areas, Eastern Europe, Central and South America, Africa except
                  Egypt, Russia, Asia, Indonesia

               -  Oral body temperature of &gt; 37.7°C on Day -1, or as judged by the Investigator.

               -  Blood neutrophil count &lt; 1.7 x109/L (Screening and Day -1 morning sample).

               -  Is in high risk-group for HIV infection within the last 6 months (i.e., men who
                  have had unprotected sex with men, women who have had sex without a condom with
                  men who have sex with men, people who have had sex without a condom with a person
                  who has lived or travelled in Africa, people who inject drugs, people who have
                  had sex without a condom with somebody who has injected drugs, people who have
                  caught another sexually transmitted infection, people who have received a blood
                  transfusion while in Africa, eastern Europe, the countries of the former Soviet
                  Union, Asia or central and southern America).

               -  Other latent or chronic infections (e.g., recurrent sinusitis, genital or ocular
                  herpes, urinary tract infection) or at risk of infection (surgery, trauma, or
                  significant infection) within 90 days of screening, or history of skin abscesses
                  within 90 days of screening.

               -  Clinically significant lower respiratory tract infection not resolved within 4
                  weeks prior to screening, as determined by the Investigator.

               -  Volunteers with active malignancy or neoplastic disease in the previous 5 years
                  other than superficial basal cell carcinoma.

               -  Disease history suggesting abnormal immune function.

               -  Volunteers who have received live or live-attenuated vaccine in the 4 weeks prior
                  to dosing.

               -  High-sensitivity C-reactive protein above upper limit of laboratory reference
                  range at screening and on Day -1.

          -  Some subjects lacking functional dipeptidyl peptidase 1 (DPP1) enzyme have been
             described to have periodontitis and palmoplantar hyperkeratosis:

               -  For Part 1a and Part 1b: Subjects with signs of current gingivitis/periodontitis.
                  Gingival evaluation (by inspection) will be performed by a dental hygienist or
                  trained study physician.

               -  For Part 2: Subjects with a history of recurring gingivitis/periodontitis or
                  signs of current gingivitis/periodontitis. Gingival evaluation will be performed
                  by a dental hygienist or trained study physician. Evaluation of bleeding
                  propensity due to gingivitis will be performed by using dental hygienist
                  instrumentation. Exact measurement of gum pockets is not needed.

               -  Subjects with a history of hyperkeratosis or erythema in palms or soles.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annelize Koch, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase Clinical Unit, Level 7, Northwick Park Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ, United Kingdom</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bengt Larsson</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 3, 2014</study_first_submitted>
  <study_first_submitted_qc>November 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <results_first_submitted>July 10, 2017</results_first_submitted>
  <results_first_submitted_qc>December 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2018</results_first_posted>
  <last_update_submitted>December 10, 2018</last_update_submitted>
  <last_update_submitted_qc>December 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD7986, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect, First-in-human, Single Ascending Dose, Multiple Ascending Dose, Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at PAREXEL Early Phase Clinical Unit London, Level 7, Northwick Park Hospital in London. Healthy male and female participants were enrolled.</recruitment_details>
      <pre_assignment_details>In Part 1 and Part 2, participants underwent a screening visit within 28 days before receiving the first dose of investigational medicinal product (IMP). Participants were admitted to the study centre 1 day before administration of the IMP (Day -1).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD7986 5 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
        </group>
        <group group_id="P2">
          <title>AZD7986 15 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1in fasted state.</description>
        </group>
        <group group_id="P3">
          <title>AZD7986 35 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
        </group>
        <group group_id="P4">
          <title>AZD7986 50 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1 in fasted state.</description>
        </group>
        <group group_id="P5">
          <title>AZD7986 65 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1 in fasted state.</description>
        </group>
        <group group_id="P6">
          <title>AZD7986 35 mg (Fed State) - SAD</title>
          <description>Participants of Cohorts 3 from Part 1a received single dose of oral solution of AZD7986 35 mg on Day 1 in fed state after a washout of at least 7 days.</description>
        </group>
        <group group_id="P7">
          <title>AZD7986 10 mg - MAD</title>
          <description>Participants received single dose (morning) of oral solution of AZD7986 10 mg for 28 days (fasted or fed state, depending on Part 1b results). Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
        </group>
        <group group_id="P8">
          <title>AZD7986 25 mg - MAD</title>
          <description>Participants received single dose (morning) of oral solution of AZD7986 25 mg for 28 days (fasted or fed state, depending on Part 1b results). Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
        </group>
        <group group_id="P9">
          <title>AZD7986 40 mg - MAD</title>
          <description>Participants received single dose (morning) of oral solution of AZD7986 40 mg for 28 days (fasted or fed state, depending on Part 1b results). Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
        </group>
        <group group_id="P10">
          <title>Placebo</title>
          <description>Randomized participants received orally AZD7986 matching placebo oral solution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1a (Fasted State)- SAD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="15">Participants received AZD7986 matching placebo on Day 1 in fasted state.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1b (Fed State) - SAD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3">Participants received AZD7986 matching placebo on Day 1 in fed state.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 - Multiple Ascending Dose (MAD)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="12">Participants took AZD7986 matching placebo for 28 days (fasted/fed state, based on part 1b results)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD7986 5 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
        </group>
        <group group_id="B2">
          <title>AZD7986 15 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1in fasted state.</description>
        </group>
        <group group_id="B3">
          <title>AZD7986 35 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
        </group>
        <group group_id="B4">
          <title>AZD7986 50 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1 in fasted state.</description>
        </group>
        <group group_id="B5">
          <title>AZD7986 65 mg (Fasted State) - SAD</title>
          <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1 in fasted state.</description>
        </group>
        <group group_id="B6">
          <title>AZD7986 35 mg (Fed State) - SAD</title>
          <description>Participants of Cohorts 3 from Part 1a received single dose of oral solution of AZD7986 35 mg on Day 1 in fed state after a washout of at least 7 days.</description>
        </group>
        <group group_id="B7">
          <title>AZD7986 10 mg - MAD</title>
          <description>Participants received single dose (morning) of oral solution of AZD7986 10 mg for 28 days (fasted or fed state, depending on Part 1b results). Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
        </group>
        <group group_id="B8">
          <title>AZD7986 25 mg - MAD</title>
          <description>Participants received single dose (morning) of oral solution of AZD7986 25 mg for 28 days (fasted or fed state, depending on Part 1b results). Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
        </group>
        <group group_id="B9">
          <title>AZD7986 40 mg - MAD</title>
          <description>Participants received single dose (morning) of oral solution of AZD7986 40 mg for 28 days (fasted or fed state, depending on Part 1b results). Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
        </group>
        <group group_id="B10">
          <title>Placebo - Part 1a (Fasted)</title>
          <description>Randomized participants received orally AZD7986 matching placebo oral solution on Day 1 in fasted state.</description>
        </group>
        <group group_id="B11">
          <title>Placebo - Part 1b (Fed State)</title>
          <description>Randomized participants received orally AZD7986 matching placebo oral solution on Day 1 in fed state.</description>
        </group>
        <group group_id="B12">
          <title>Placebo - Part 2</title>
          <description>Randomized participants received orally AZD7986 matching placebo oral solution for 28 days (fasted/fed state, based on part 1b results).</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="10"/>
            <count group_id="B10" value="15"/>
            <count group_id="B11" value="3"/>
            <count group_id="B12" value="12"/>
            <count group_id="B13" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>All randomized participants who received at least one dose of IMP were included for the presentation of all demographic data.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part 1a</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" spread="5.39"/>
                    <measurement group_id="B2" value="29.7" spread="8.78"/>
                    <measurement group_id="B3" value="26.2" spread="3.66"/>
                    <measurement group_id="B4" value="32.2" spread="10.5"/>
                    <measurement group_id="B5" value="29.7" spread="6.65"/>
                    <measurement group_id="B13" value="29.2" spread="7.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 1b</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="5"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="26.6" spread="3.91"/>
                    <measurement group_id="B13" value="26.6" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="8"/>
                    <count group_id="B9" value="10"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B7" value="30.7" spread="5.65"/>
                    <measurement group_id="B8" value="38.4" spread="7.25"/>
                    <measurement group_id="B9" value="34.4" spread="9.17"/>
                    <measurement group_id="B13" value="34.8" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 1a Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="15"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B10" value="29.9" spread="7.24"/>
                    <measurement group_id="B13" value="29.9" spread="7.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 1b Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="3"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B11" value="28.7" spread="8.5"/>
                    <measurement group_id="B13" value="28.7" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2 Placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="12"/>
                    <count group_id="B13" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B12" value="36.2" spread="7.2"/>
                    <measurement group_id="B13" value="36.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>All randomised subjects who received at least one dose of IMP were included for the presentation of all demographic data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Part 1a</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="15"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="15"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 1b</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="5"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="3"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="8"/>
                    <count group_id="B9" value="10"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="12"/>
                    <count group_id="B13" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a and 1b) and Multiple Ascending Doses (MAD -Part 2)</title>
        <description>To investigate the safety and tolerability of AZD7986 by assessment of AEs (non-serious and serious) following administration of oral solution in SAD (Part 1a - fasted state and 1b - fed state) and MAD (Part 2)</description>
        <time_frame>Part 1a and 1b: Day -1, Day 1 to Day 3 (spontaneous, at pre-dose, 3, 12, 24, 48 and 72 hours [h] post-dose), Day 4, Day 5 and follow-up (7-10 days after dosing [not for participants included in Part 1b]); Part 2: Day -1, Day 1 to Day 21/28 and follow-up</time_frame>
        <population>All randomized subjects who received at least one dose of IMP were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1a (Fasted State) - Single Ascending Dose (SAD)</title>
            <description>Participants received single dose of oral solution of AZD7986 at 5 ascending doses (5mg, 15mg, 35mg, 50mg and 65mg) on Day 1 in fasted state with 6 participants in each dose level.</description>
          </group>
          <group group_id="O2">
            <title>Part 1b (Fed State) - SAD</title>
            <description>5 Participants of Cohort 3 from Part 1a received single dose of oral solution of AZD7986 35mg on Day 1 in fed state after a washout of at least 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Part 2 - Multiple Ascending Dose (MAD)</title>
            <description>24 participants (6 in Cohort 1-10mg, 8 in Cohort 2- 25mg and 10 in Cohort 3-40mg) received once daily dose of oral solution of AZD7986 in the morning for 28 days. Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Part 1a (Fasted State)- SAD</title>
            <description>3 participants per dose level received single dose of oral solution of placebo in Part 1a in fasted state on Day 1</description>
          </group>
          <group group_id="O5">
            <title>Placebo - Part 1b (Fed State) - SAD</title>
            <description>3 participants of Cohort 3 from Part 1a received single dose of oral solution of placebo 35mg on Day 1 in fed state after a washout of at least 7 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo - Part 2 - MAD</title>
            <description>12 participants (randomized 6:3, 8:3 and 10:4/10:6/12:4) received once daily dose of oral solution of Placebo in the morning for 28 days. Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a and 1b) and Multiple Ascending Doses (MAD -Part 2)</title>
          <description>To investigate the safety and tolerability of AZD7986 by assessment of AEs (non-serious and serious) following administration of oral solution in SAD (Part 1a - fasted state and 1b - fed state) and MAD (Part 2)</description>
          <population>All randomized subjects who received at least one dose of IMP were included in the safety analysis for the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE with outcome = death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious adverse event (SAE) (including death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to discontinuation of AZD7986</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD</title>
        <description>To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD</title>
          <description>To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>h·nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839.0" spread="48.3"/>
                    <measurement group_id="O2" value="3855" spread="9.3"/>
                    <measurement group_id="O3" value="12430" spread="18.3"/>
                    <measurement group_id="O4" value="16470" spread="22.7"/>
                    <measurement group_id="O5" value="22880" spread="21.2"/>
                    <measurement group_id="O6" value="10790" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD</title>
        <description>To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD</title>
          <description>To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>h·nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1278" spread="18.9" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="3256" spread="15.9" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="6427" spread="31.0" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="5135" spread="49.4"/>
                    <measurement group_id="O5" value="14320" spread="39.5"/>
                    <measurement group_id="O6" value="29550" spread="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD</title>
        <description>To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD</title>
          <description>To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>h·nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="915.3" spread="46.1"/>
                    <measurement group_id="O2" value="4165" spread="10.8"/>
                    <measurement group_id="O3" value="13230" spread="19.6"/>
                    <measurement group_id="O4" value="17590" spread="25.2"/>
                    <measurement group_id="O5" value="24710" spread="21.5"/>
                    <measurement group_id="O6" value="11550" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality was analyzed by power model. Slope parameter was obtained via linear least squares.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>1.287</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05085</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.183</ci_lower_limit>
            <ci_upper_limit>1.391</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Effect of food analysis by linear mixed effects ANOVA model with fixed effect of fasting status.</non_inferiority_desc>
            <param_type>Ratio (%)</param_type>
            <param_value>90.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.72</ci_lower_limit>
            <ci_upper_limit>98.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD</title>
        <description>To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Note: Day 1 data calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD</title>
          <description>To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Note: Day 1 data calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>h·nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1778" spread="21.3" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="4957" spread="19.5" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="9866" spread="35.8" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="5565" spread="54.3"/>
                    <measurement group_id="O5" value="16660" spread="44.2"/>
                    <measurement group_id="O6" value="33220" spread="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Time dependency was assessed via linear mixed effects ANOVA model with fixed effects of dose level, day and dose-level-by-day interaction.</non_inferiority_desc>
            <param_type>Ratio (%)</param_type>
            <param_value>159.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>140.61</ci_lower_limit>
            <ci_upper_limit>180.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Time dependency was assessed via linear mixed effects ANOVA model with fixed effects of dose level, day and dose-level-by-day interaction.</non_inferiority_desc>
            <param_type>Ratio (%)</param_type>
            <param_value>151.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>138.23</ci_lower_limit>
            <ci_upper_limit>166.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Time dependency was assessed via linear mixed effects ANOVA model with fixed effects of dose level, day and dose-level-by-day interaction.</non_inferiority_desc>
            <param_type>Ratio (%)</param_type>
            <param_value>158.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>146.67</ci_lower_limit>
            <ci_upper_limit>171.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD</title>
        <description>To assess area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCτ) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. AUCτ: AUC from time zero to 24 hours post-dose presented on Day1</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD</title>
          <description>To assess area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCτ) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. AUCτ: AUC from time zero to 24 hours post-dose presented on Day1</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>h·nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1277" spread="18.9" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="3259" spread="15.9" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="6433" spread="31.0" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="2834" spread="35.1"/>
                    <measurement group_id="O5" value="7499" spread="27.4"/>
                    <measurement group_id="O6" value="15660" spread="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality was analyzed by power model. Slope parameter was obtained via linear least squares.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>1.228</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1329</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9513</ci_lower_limit>
            <ci_upper_limit>1.504</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ime dependency was assessed via linear mixed effects ANOVA model with fixed effects of dose level, day and dose-level-by-day interaction.</non_inferiority_desc>
            <param_type>Ratio (%)</param_type>
            <param_value>159.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>140.61</ci_lower_limit>
            <ci_upper_limit>180.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ime dependency was assessed via linear mixed effects ANOVA model with fixed effects of dose level, day and dose-level-by-day interaction.</non_inferiority_desc>
            <param_type>Ratio (%)</param_type>
            <param_value>151.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>138.23</ci_lower_limit>
            <ci_upper_limit>166.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ime dependency was assessed via linear mixed effects ANOVA model with fixed effects of dose level, day and dose-level-by-day interaction.</non_inferiority_desc>
            <param_type>Ratio (%)</param_type>
            <param_value>158.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>146.67</ci_lower_limit>
            <ci_upper_limit>171.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD</title>
        <description>To assess the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD</title>
          <description>To assess the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.74" spread="47.2"/>
                    <measurement group_id="O2" value="202.3" spread="16.0"/>
                    <measurement group_id="O3" value="668.1" spread="26.7"/>
                    <measurement group_id="O4" value="1035" spread="11.5"/>
                    <measurement group_id="O5" value="1358" spread="24.2"/>
                    <measurement group_id="O6" value="434.8" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was analyzed by power model. Slope parameter was obtained via linear least squares.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.302</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.198</ci_lower_limit>
            <ci_upper_limit>1.406</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Effect of food analysis by linear mixed effects ANOVA model with fixed effect of fasting status.</non_inferiority_desc>
            <param_type>Ratio (%)</param_type>
            <param_value>64.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.07</ci_lower_limit>
            <ci_upper_limit>74.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD</title>
        <description>To assessthe observed maximum plasma concentration (Cmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Cmax was taken directly from the individual concentration-time curve</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD</title>
          <description>To assessthe observed maximum plasma concentration (Cmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Cmax was taken directly from the individual concentration-time curve</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.6" spread="18.3" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="350.9" spread="19.3" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="672.0" spread="37.0" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="246.3" spread="26.2"/>
                    <measurement group_id="O5" value="598.1" spread="15.5"/>
                    <measurement group_id="O6" value="1235" spread="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose proportionality was analyzed by power model. Slope parameter was obtained via linear least squares.</non_inferiority_desc>
            <param_type>Slope</param_type>
            <param_value>1.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1098</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9285</ci_lower_limit>
            <ci_upper_limit>1.385</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD</title>
        <description>To assess the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD</title>
          <description>To assess the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="47.2" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.75" spread="16.0" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.75" spread="26.7" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.64" spread="11.5" lower_limit="0.52" upper_limit="0.75"/>
                    <measurement group_id="O5" value="0.75" spread="24.2" lower_limit="0.52" upper_limit="1.98"/>
                    <measurement group_id="O6" value="4.00" spread="14.0" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD</title>
        <description>To assess the time to reach maximum observed concentration (tmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD</title>
          <description>To assess the time to reach maximum observed concentration (tmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="21.3" lower_limit="0.52" upper_limit="1.53"/>
                    <measurement group_id="O2" value="0.75" spread="19.5" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.75" spread="35.8" lower_limit="0.52" upper_limit="1.50"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.75" upper_limit="1.50"/>
                    <measurement group_id="O5" value="0.75" lower_limit="0.52" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.12" lower_limit="0.53" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD</title>
        <description>To assess the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD</title>
          <description>To assess the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.96" spread="3.416" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="25.92" spread="4.452" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="23.80" spread="3.328" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="24.52" spread="5.836" lower_limit="0.52" upper_limit="0.75"/>
                    <measurement group_id="O5" value="25.50" spread="7.254" lower_limit="0.52" upper_limit="1.98"/>
                    <measurement group_id="O6" value="24.24" spread="4.259" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD</title>
        <description>To assess the apparent terminal elimination half-life (t½.λz) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve. Note: Day 1 data were calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD</title>
          <description>To assess the apparent terminal elimination half-life (t½.λz) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve. Note: Day 1 data were calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.82" spread="1.477" lower_limit="0.52" upper_limit="1.53"/>
                    <measurement group_id="O2" value="14.85" spread="2.244" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="15.85" spread="4.132" lower_limit="0.52" upper_limit="1.50"/>
                    <measurement group_id="O4" value="25.85" spread="5.501"/>
                    <measurement group_id="O5" value="33.78" spread="10.31"/>
                    <measurement group_id="O6" value="30.04" spread="5.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD</title>
        <description>To assess the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD</title>
          <description>To assess the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.03" spread="4.373" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="34.94" spread="5.863" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="32.15" spread="5.003" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="32.19" spread="8.360" lower_limit="0.52" upper_limit="0.75"/>
                    <measurement group_id="O5" value="33.76" spread="10.35" lower_limit="0.52" upper_limit="1.98"/>
                    <measurement group_id="O6" value="33.73" spread="6.429" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD</title>
        <description>To assess the mean residence time (MRT) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD</title>
          <description>To assess the mean residence time (MRT) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.56" spread="2.245" lower_limit="0.52" upper_limit="1.53"/>
                    <measurement group_id="O2" value="21.84" spread="3.067" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="22.64" spread="5.844" lower_limit="0.52" upper_limit="1.50"/>
                    <measurement group_id="O4" value="33.73" spread="9.663"/>
                    <measurement group_id="O5" value="40.16" spread="10.58"/>
                    <measurement group_id="O6" value="37.46" spread="8.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD</title>
        <description>To assess the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD</title>
          <description>To assess the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Litre/Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.23" spread="7.577" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="8.606" spread="0.9321" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="6.395" spread="1.281" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="6.938" spread="1.777" lower_limit="0.52" upper_limit="0.75"/>
                    <measurement group_id="O5" value="6.371" spread="1.317" lower_limit="0.52" upper_limit="1.98"/>
                    <measurement group_id="O6" value="7.363" spread="1.810" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD</title>
        <description>To assess the apparent clearance (CL/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; CL/F for parent drug was estimated as dose divided by AUC</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD</title>
          <description>To assess the apparent clearance (CL/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; CL/F for parent drug was estimated as dose divided by AUC</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Litre/Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.61" spread="2.665" lower_limit="0.52" upper_limit="1.53"/>
                    <measurement group_id="O2" value="12.20" spread="2.485" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="10.24" spread="4.206" lower_limit="0.52" upper_limit="1.50"/>
                    <measurement group_id="O4" value="8.786" spread="2.772"/>
                    <measurement group_id="O5" value="8.165" spread="2.025"/>
                    <measurement group_id="O6" value="6.577" spread="2.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD</title>
        <description>To assess the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD</title>
          <description>To assess the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385.1" spread="129.6" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="318.8" spread="46.72" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="215.8" spread="29.62" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="236.8" spread="39.64" lower_limit="0.52" upper_limit="0.75"/>
                    <measurement group_id="O5" value="231.0" spread="67.56" lower_limit="0.52" upper_limit="1.98"/>
                    <measurement group_id="O6" value="249.5" spread="24.96" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD</title>
        <description>To assess the the apparent volume of distribution (Vz/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD</title>
          <description>To assess the the apparent volume of distribution (Vz/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248.9" spread="38.94" lower_limit="0.52" upper_limit="1.53"/>
                    <measurement group_id="O2" value="256.7" spread="36.11" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="222.7" spread="65.93" lower_limit="0.52" upper_limit="1.50"/>
                    <measurement group_id="O4" value="311.8" spread="56.96"/>
                    <measurement group_id="O5" value="393.2" spread="163.1"/>
                    <measurement group_id="O6" value="269.6" spread="79.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MAD</title>
        <description>To assess the accumulation ratio for (Rac(AUC(0-τ)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC(0-24) Day 1</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MAD</title>
          <description>To assess the accumulation ratio for (Rac(AUC(0-τ)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC(0-24) Day 1</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O4" value="2.257" spread="0.4560"/>
                    <measurement group_id="O5" value="2.330" spread="0.4828"/>
                    <measurement group_id="O6" value="2.476" spread="0.4521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MAD</title>
        <description>To assess the accumulation ratio for Cmax (Rac(Cmax)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as Cmax Day 21/Cmax Day 1</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MAD</title>
          <description>To assess the accumulation ratio for Cmax (Rac(Cmax)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as Cmax Day 21/Cmax Day 1</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O4" value="1.799" spread="0.3084"/>
                    <measurement group_id="O5" value="1.667" spread="0.2007"/>
                    <measurement group_id="O6" value="1.881" spread="0.4015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MAD</title>
        <description>To assess the temporal change parameter (TCP) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC Day 1, if extrapolated part was less than 20%</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MAD</title>
          <description>To assess the temporal change parameter (TCP) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC Day 1, if extrapolated part was less than 20%</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O4" value="1.610" spread="0.2539"/>
                    <measurement group_id="O5" value="1.535" spread="0.2479"/>
                    <measurement group_id="O6" value="1.599" spread="0.2082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD</title>
        <description>To assess cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD</title>
          <description>To assess cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1318" spread="348.5" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="4820" spread="1096" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="16530" spread="2145" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O4" value="19660" spread="4521" lower_limit="0.52" upper_limit="0.75"/>
                    <measurement group_id="O5" value="27770" spread="10200" lower_limit="0.52" upper_limit="1.98"/>
                    <measurement group_id="O6" value="18420" spread="2554" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD</title>
        <description>To assess percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD</title>
          <description>To assess percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Percentage of dose excreted unchanged</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.09" spread="2.931"/>
                    <measurement group_id="O2" value="13.51" spread="3.074"/>
                    <measurement group_id="O3" value="19.86" spread="2.578"/>
                    <measurement group_id="O4" value="16.53" spread="3.802"/>
                    <measurement group_id="O5" value="17.97" spread="6.598"/>
                    <measurement group_id="O6" value="22.13" spread="3.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD</title>
        <description>To assess renal clearance from 0 to 48 hours (CLR0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 5mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 5mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 15mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 15mg on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 50mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 50mg on Day 1</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 65mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 65mg on Day 1</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD</title>
          <description>To assess renal clearance from 0 to 48 hours (CLR0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Liter/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.734" spread="0.368"/>
                    <measurement group_id="O2" value="1.544" spread="0.2898"/>
                    <measurement group_id="O3" value="1.619" spread="0.2101"/>
                    <measurement group_id="O4" value="1.430" spread="0.1561"/>
                    <measurement group_id="O5" value="1.477" spread="0.5187"/>
                    <measurement group_id="O6" value="2.097" spread="0.1921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD</title>
        <description>To assess cumulative amount of analyte excreted from 0 to 24 hours (CumAe0-24) for Part 2</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD</title>
          <description>To assess cumulative amount of analyte excreted from 0 to 24 hours (CumAe0-24) for Part 2</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2295" spread="638.1" lower_limit="0.52" upper_limit="1.53"/>
                    <measurement group_id="O2" value="5540" spread="1305" lower_limit="0.53" upper_limit="2.00"/>
                    <measurement group_id="O3" value="11390" spread="2415" lower_limit="0.52" upper_limit="1.50"/>
                    <measurement group_id="O4" value="4002" spread="1402"/>
                    <measurement group_id="O5" value="11960" spread="4665"/>
                    <measurement group_id="O6" value="24970" spread="8075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD</title>
        <description>To assess the effect of food by evaluating the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD</title>
          <description>To assess the effect of food by evaluating the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>h·nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12430" spread="18.3"/>
                    <measurement group_id="O2" value="10790" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD</title>
        <description>To assess the effect of food by evaluating the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD</title>
          <description>To assess the effect of food by evaluating the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>h·nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13230" spread="19.6"/>
                    <measurement group_id="O2" value="11550" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD</title>
        <description>To assess the effect of food by evaluating the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD</title>
          <description>To assess the effect of food by evaluating the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668.1" spread="26.7"/>
                    <measurement group_id="O2" value="434.8" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD</title>
        <description>To assess the effect of food by evaluating the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD</title>
          <description>To assess the effect of food by evaluating the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="26.7" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O2" value="4.00" spread="14.0" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD</title>
        <description>To assess the effect of food by evaluating the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD</title>
          <description>To assess the effect of food by evaluating the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.80" spread="3.328" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O2" value="24.24" spread="4.259" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD</title>
        <description>To assess the effect of food by evaluating the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD</title>
          <description>To assess the effect of food by evaluating the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.15" spread="5.003" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O2" value="33.73" spread="6.429" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD</title>
        <description>To assess the effect of food by evaluating the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD</title>
          <description>To assess the effect of food by evaluating the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Litre/Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.395" spread="1.281" lower_limit="0.53" upper_limit="1.50"/>
                    <measurement group_id="O2" value="7.363" spread="1.810" lower_limit="3.00" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD</title>
        <description>To assess the effect of food by evaluating the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz</description>
        <time_frame>At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 35mg - Part 1a (Fasted State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 35mg - Part 1b (Fed State) - SAD</title>
            <description>Participants received single dose of oral solution of AZD7986 35mg on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD</title>
          <description>To assess the effect of food by evaluating the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.8" spread="29.62"/>
                    <measurement group_id="O2" value="249.5" spread="24.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Mean Normalized Relative Neutrophil Elastase (NE) Activity in All Cohorts of Part 2</title>
        <description>Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker</description>
        <time_frame>At Day 16, 21 ((last dosing day in Cohort 1), 25, 28 (last sampling day in Cohort 1 and last dosing day in Cohorts 2 and 3), 32, 38, 41 and 52</time_frame>
        <population>All participants who receiving at least 1 dose of AZD7986 or placebo and who had at least 1 pre-dose and 1 post-dose measurement for either NE (NE1 or NE2), and who had no major protocol deviations thought to impact on the analysis of the PD data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Part 2 - MAD</title>
            <description>12 participants (randomized 6:3, 8:3 and 10:4/10:6/12:4) received once daily dose of oral solution of Placebo in the morning for 28 days. Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Mean Normalized Relative Neutrophil Elastase (NE) Activity in All Cohorts of Part 2</title>
          <description>Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker</description>
          <population>All participants who receiving at least 1 dose of AZD7986 or placebo and who had at least 1 pre-dose and 1 post-dose measurement for either NE (NE1 or NE2), and who had no major protocol deviations thought to impact on the analysis of the PD data</population>
          <units>Percentage change in NE activity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.53" spread="11.59"/>
                    <measurement group_id="O2" value="-28.25" spread="22.33"/>
                    <measurement group_id="O3" value="-28.10" spread="16.87"/>
                    <measurement group_id="O4" value="7.39" spread="13.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.13" spread="3.116"/>
                    <measurement group_id="O2" value="-36.73" spread="11.76"/>
                    <measurement group_id="O3" value="-52.31" spread="14.90"/>
                    <measurement group_id="O4" value="1.39" spread="20.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.15" spread="8.412"/>
                    <measurement group_id="O2" value="-40.06" spread="6.609"/>
                    <measurement group_id="O3" value="-59.02" spread="11.77"/>
                    <measurement group_id="O4" value="-5.15" spread="14.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.22" spread="9.141"/>
                    <measurement group_id="O2" value="-45.05" spread="8.304"/>
                    <measurement group_id="O3" value="-55.24" spread="9.087"/>
                    <measurement group_id="O4" value="-16.36" spread="22.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA: not applicable.</measurement>
                    <measurement group_id="O2" value="-53.35" spread="8.292"/>
                    <measurement group_id="O3" value="-46.29" spread="37.55"/>
                    <measurement group_id="O4" value="-6.216" spread="14.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA: not applicable.</measurement>
                    <measurement group_id="O2" value="-54.42" spread="6.800"/>
                    <measurement group_id="O3" value="-65.44" spread="7.556"/>
                    <measurement group_id="O4" value="-19.51" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 41</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA: not applicable.</measurement>
                    <measurement group_id="O2" value="-53.46" spread="9.774"/>
                    <measurement group_id="O3" value="-62.56" spread="8.324"/>
                    <measurement group_id="O4" value="-18.14" spread="15.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA: not applicable.</measurement>
                    <measurement group_id="O2" value="-17.73" spread="18.07"/>
                    <measurement group_id="O3" value="-21.31" spread="18.07"/>
                    <measurement group_id="O4" value="-20.98" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Absolute Neutrophil Count (ANC) in All Cohorts of Part 2</title>
        <description>Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker</description>
        <time_frame>At Day 12 (pre-dose, 6 hours and 12 hours)</time_frame>
        <population>All participants who receiving at least 1 dose of AZD7986 or placebo and who had at least 1 pre-dose and 1 post-dose measurement for either NE (NE1 or NE2), and who had no major protocol deviations thought to impact on the analysis of the PD data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Part 2 - MAD</title>
            <description>12 participants (randomized 6:3, 8:3 and 10:4/10:6/12:4) received once daily dose of oral solution of Placebo in the morning for 28 days. Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Absolute Neutrophil Count (ANC) in All Cohorts of Part 2</title>
          <description>Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker</description>
          <population>All participants who receiving at least 1 dose of AZD7986 or placebo and who had at least 1 pre-dose and 1 post-dose measurement for either NE (NE1 or NE2), and who had no major protocol deviations thought to impact on the analysis of the PD data</population>
          <units>10^9 neutrophils/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 12, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.757" spread="0.4178"/>
                    <measurement group_id="O2" value="2.881" spread="0.5222"/>
                    <measurement group_id="O3" value="2.560" spread="0.9108"/>
                    <measurement group_id="O4" value="2.945" spread="0.7966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12, 6 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA: not applicable. Not assessed for AZD7986 10 mg.</measurement>
                    <measurement group_id="O2" value="3.401" spread="1.049"/>
                    <measurement group_id="O3" value="3.129" spread="0.7210"/>
                    <measurement group_id="O4" value="3.402" spread="1.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12, 12 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA: not applicable. Not assessed for AZD7986 10 mg.</measurement>
                    <measurement group_id="O2" value="3.454" spread="0.7448"/>
                    <measurement group_id="O3" value="3.460" spread="0.5248"/>
                    <measurement group_id="O4" value="3.247" spread="0.7622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD</title>
        <description>To assess percentage of dose excreted unchanged into the urine from 0 to 24 hours (Cumfe0 24) for Part 2</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD</title>
          <description>To assess percentage of dose excreted unchanged into the urine from 0 to 24 hours (Cumfe0 24) for Part 2</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Percentage of dose excreted unchanged</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.650" spread="2.683" lower_limit="0.75" upper_limit="1.50"/>
                    <measurement group_id="O2" value="9.319" spread="2.195" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="11.98" spread="2.539" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="16.83" spread="5.894"/>
                    <measurement group_id="O5" value="20.12" spread="7.847"/>
                    <measurement group_id="O6" value="26.25" spread="8.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD</title>
        <description>To assess renal clearance from 0 to 24 hours (CLR0-24) for Part 2</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD</title>
          <description>To assess renal clearance from 0 to 24 hours (CLR0-24) for Part 2</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Liter/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.784" spread="0.4606" lower_limit="0.75" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.685" spread="0.3441" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="1.782" spread="0.3841" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="NA" spread="NA">NA - Not applicable</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">NA - Not applicable</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">NA - Not applicable</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MAD</title>
        <description>To assess Cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48)) for Part 2</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MAD</title>
          <description>To assess Cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48)) for Part 2</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O4" value="6525" spread="2684"/>
                    <measurement group_id="O5" value="18680" spread="8765"/>
                    <measurement group_id="O6" value="36160" spread="12030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MAD</title>
        <description>To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MAD</title>
          <description>To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Percentage of dose excreted unchanged</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O4" value="27.44" spread="11.29"/>
                    <measurement group_id="O5" value="31.42" spread="14.74"/>
                    <measurement group_id="O6" value="38.01" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MAD</title>
        <description>To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2</description>
        <time_frame>Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28</time_frame>
        <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7986 10mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>AZD7986 25mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>AZD7986 40mg - Day 1 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
          <group group_id="O4">
            <title>AZD7986 10mg - Day 21 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 10mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>AZD7986 25mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 25mg on Day 1 and daily dosing on Days 21 or 28 in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>AZD7986 40mg - Day 28 - Part 2 - MAD</title>
            <description>Participants received single dose of oral solution of AZD7986 40mg on Day 1 and daily dosing on Days 21 or 28 I fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MAD</title>
          <description>To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2</description>
          <population>The pharmacokinetic analysis (PK) analysis set consisted of all subjects in the safety analysis set who received at least 1 dose of AZD7986 and had evaluable PK data.</population>
          <units>Liter/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">NA - Not applicable. Not assessed for Day 1</measurement>
                    <measurement group_id="O4" value="1.508" spread="0.438"/>
                    <measurement group_id="O5" value="1.618" spread="0.5085"/>
                    <measurement group_id="O6" value="1.527" spread="0.3418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1a and 1b: Day -1, Day 1 to Day 3 (spontaneous, at pre-dose, 3, 12, 24, 48 and 72 hours [h] post-dose), Day 4, Day 5 and follow-up (7-10 days after dosing [not for participants included in Part 1b]); Part 2: Day -1, Day 1 to Day 21/28 and follow-up</time_frame>
      <desc>All randomized participants who received at least 1 dose of IMP were included in the safety analysis.
Adverse events (AEs - serious / non-serious), an undesirable medical condition occurring at any time after the participant had signed informed consent, including run-in or washout periods, even if no specific treatment has been administered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1a (Fasted State) - Single Ascending Dose (SAD)</title>
          <description>Participants received single dose of oral solution of AZD7986 at 5 ascending doses (5mg, 15mg, 35mg, 50mg and 65mg) on Day 1 in fasted state with 6 participants in each dose level.</description>
        </group>
        <group group_id="E2">
          <title>Part 1b (Fed State) - SAD</title>
          <description>5 Participants of Cohort 3 from Part 1a received single dose of oral solution of AZD7986 35mg on Day 1 in fed state after a washout of at least 7 days.</description>
        </group>
        <group group_id="E3">
          <title>Part 2 - Multiple Ascending Dose (MAD)</title>
          <description>24 participants (6 in Cohort 1-10mg, 8 in Cohort 2- 25mg and 10 in Cohort 3-40mg) received once daily dose of oral solution of AZD7986 in the morning for 28 days. Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
        </group>
        <group group_id="E4">
          <title>Placebo - Part 1a (Fasted State)- SAD</title>
          <description>3 participants per dose level received single dose of oral solution of placebo in Part 1a in fasted state on Day 1</description>
        </group>
        <group group_id="E5">
          <title>Placebo - Part 1b (Fed State) - SAD</title>
          <description>3 participants of Cohort 3 from Part 1a received single dose of oral solution of placebo 35mg on Day 1 in fed state after a washout of at least 7 days.</description>
        </group>
        <group group_id="E6">
          <title>Placebo - Part 2 - MAD</title>
          <description>12 participants (randomized 6:3, 8:3 and 10:4/10:6/12:4) received once daily dose of oral solution of Placebo in the morning for 28 days. Participants were fasted until 1 hour after dosing when a light breakfast was provided.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive cerumen production</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bengt Larsson</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+46 766 346712</phone>
      <email>clinicaltrialtransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

